62243-52-1

Basic information

• Product Name: 3-(cyclopropylmethyl-amino)-5-(dimethylaminomethylene-sulfamoyl)-4-phenoxy-benzoic acid methyl ester
• Synonyms: 3-(cyclopropylmethyl-amino)-5-(dimethylaminomethylene-sulfamoyl)-4-phenoxy-benzoic acid methyl ester
• CAS NO: 62243-52-1
• Molecular Weight: 431.513
• Mol File: 62243-52-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(cyclopropylmethyl-amino)-5-(dimethylaminomethylene-sulfamoyl)-4-phenoxy-benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(cyclopropylmethyl-amino)-5-(dimethylaminomethylene-sulfamoyl)-4-phenoxy-benzoic acid methyl ester(62243-52-1)
• EPA Substance Registry System: 3-(cyclopropylmethyl-amino)-5-(dimethylaminomethylene-sulfamoyl)-4-phenoxy-benzoic acid methyl ester(62243-52-1)

Safety Data

• Hazardous Substances Data: 62243-52-1(Hazardous Substances Data)

Upstream product

• 60376-73-0 3-(dimethylaminomethylenesulfamoyl)-5-nitro-4-phenoxybenzoic acid methyl ester 
• 60376-74-1 5-amino-3-(dimethylaminomethylenesulfamoyl)-4-phenoxybenzoic acid methyl ester 
• 7051-34-5 cyclopropylcarbinyl bromide 

Relevant articles and documents

ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (autism), bipolar disorder, cancer, the improvement of cognitive function, cognitive impairment, cognitive dysfunction, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, periodic limb movement disorder (PLMD), personality disorders, postherpetic neuralgia, psychosis, restless legs syndrome (RLS), schizophrenia, seizure disorders, spasticity, tinnitus, and withdrawal syndromes.